Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2003 Aug;112(3):321-3.

Amyloid beta and Alzheimer disease therapeutics: the devil may be in the details.

Author information

1
Department of Neurology, Washington University School of Medicine, St Louis, Missouri 63110, USA.

Abstract

Alzheimer disease (AD) is characterized by the progressive accumulation of amyloid beta protein (Abeta) in areas of the brain serving cognitive functions such as memory and language. The first of two separate reports (see the related articles beginning on pages 415 and 440) reveals that intrinsic T cell reactivity to the self-antigen Abeta exists in many humans and increases with age. This finding has implications for the design of Abeta vaccines. The second report demonstrates that a number of FDA- approved nonsteroidal anti-inflammatory drugs are capable of lowering Abeta levels in mice. The work suggests that further testing of the therapeutic utility of these types of compounds for the potential treatment of AD is warranted.

PMID:
12897198
PMCID:
PMC166307
DOI:
10.1172/JCI19420
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center